Susquehanna Fundamental Investments’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,927	Closed	-$134K	–	1265
2024 Q4	$134K	Buy	+13,927	New	+$72.7K	﹤0.01%	1028
2023 Q3	–	Sell	-10,447	Closed	-$18.4K	–	613
2023 Q2	$18.4K	Hold	10,447	–	–	﹤0.01%	629
2023 Q1	$32.2K	Hold	10,447	–	–	﹤0.01%	931
2022 Q4	$55.4K	Buy	+10,447	New	+$47.8K	﹤0.01%	1137
2021 Q1	–	Sell	-55,691	Closed	-$611K	–	1640
2020 Q4	$611K	Sell	55,691 -10,445	-16%	-$110K	0.01%	1033
2020 Q3	$587K	Buy	+66,136	New	+$753K	0.02%	828

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna Fundamental Investments's PSTX Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 13,927 shares — an estimated $134K sold.

Susquehanna Fundamental Investments first reported a position in PSTX in Q3 2020 and held it in 6 quarters. The position peaked at $611K in Q4 2020. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Susquehanna Fundamental Investments reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 13,927 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $134K.
Susquehanna Fundamental Investments first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Susquehanna Fundamental Investments's Poseida Therapeutics, Inc. Common Stock position peaked at $611K in Q4 2020.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.